🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Advanced/Metastatic Non-Small Cell Lung Cancer

Trilaciclib in Combination With Docetaxel for Second-Line and Beyond Treatment of Locally Advanced or Metastatic NSCLC NCT06929936Phase 21 site📍 Xiamen The First Affiliated Hospital of Xiamen University · Tests: Trilaciclib combined with Docetaxel VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma NCT03556228Phase 1, Phase 215 sites📍 Santa Rosa📍 Hartford📍 Washington D.C. VM Oncology, LLC · Tests: VMD-928 100 mg Tablet, VMD-928 Tablet and Pembrolizumab (200 mg) Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance NCT07483983Phase 27 sites📍 Villejuif📍 Bordeaux📍 Dijon Gustave Roussy, Cancer Campus, Grand Paris · Tests: ASP3082 T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer NCT02133196Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: Aldesleukin, Fludarabine, Cyclophosphamide, Young TIL AB122 Platform Study NCT04999761Phase 19 sites📍 Aichi📍 Chiba📍 Ehime Taiho Pharmaceutical Co., Ltd. · Tests: AB122, AB122, TAS-116, TAS-120, TAS-115 Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer NCT06928389Phase 31 site📍 Shanghai Akeso · Tests: Ivonescimab, docetaxel, Placebo, docetaxel JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation NCT06416410Phase 337 sites📍 Hefei📍 Beijing📍 Beijing Allist Pharmaceuticals, Inc. · Tests: JAB-21822, Tislelizumab, JAB-3312, Pemetrexed, Carboplatin A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) NCT07680764Phase 274 sites📍 Washington D.C.📍 Athens📍 Lexington Bristol-Myers Squibb · Tests: Pumitamig, Imzokitug, Pemetrexed, Cisplatin, Carboplatin RGL-270 + ICI in Advanced NSCLC NCT07652125NA1 site📍 Guangzhou Guangdong Association of Clinical Trials · Tests: RGL-270 in Combination with PD-1/PD-L1 Inhibitors, Physician's Choice SOC A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01) NCT06731907Phase 241 sites📍 Lexington📍 Baltimore📍 Fargo Merck Sharp & Dohme LLC · Tests: Pembrolizumab, Carboplatin, Paclitaxel, Nab-paclitaxel, Pemetrexed A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy NCT06362369Phase 1, Phase 25 sites📍 Aurora📍 Lake Mary📍 Lebanon 7 Hills Pharma, LLC · Tests: Alintegimod, Ipilimumab, Nivolumab A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors NCT06043466Phase 12 sites📍 Hangzhou📍 Hangzhou Chongqing Precision Biotech Co., Ltd · Tests: CEA-targeted CAR-T cells Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation NCT07012031Phase 1, Phase 29 sites📍 Sacramento📍 Tampa📍 Tampa National Cancer Institute (NCI) · Tests: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 NCT04613596Phase 2, Phase 3770 sites📍 Goodyear📍 Prescott Valley📍 Safford Mirati Therapeutics Inc. · Tests: Adagrasib, Adagrasib, Adagrasib, Adagrasib, Pembrolizumab Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab NCT07510724n/a2 sites📍 Sankt Pölten📍 Frankfurt am Main Institut für Klinische Krebsforschung IKF GmbH at Krankenha… BBO-11818 in Adult Subjects With KRAS Mutant Cancer NCT06917079Phase 117 sites📍 Los Angeles📍 Sacramento📍 San Diego TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · Tests: BBO-11818, Pembrolizumab, Platinum chemotherapy (cisplatin or carboplatin), Pemetrexed, Cetuximab A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors NCT07056556Phase 11 site📍 Shanghai Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-M09D1 Effects of Genomic Profiles on Thromboembolic Risk in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer NCT07288632n/a1 site📍 Perugia University Of Perugia Trial Comparing Systemic Therapy Alone and With Local Ablative Treatment for Stage IV NSCL Cancer Patients NCT06114108NA7 sites📍 Aarau📍 Bellinzona📍 Chur Swiss Cancer Institute · Tests: Systemic therapy alone or in combination with LAT (surgery and/or radiotherapy), Surgery, Radiotherapy FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations NCT06669117Phase 1, Phase 219 sites📍 Washington D.C.📍 Canton📍 Nashville Pierre Fabre Medicament · Tests: VERT-002 A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors NCT07115043Phase 1, Phase 213 sites📍 Grand Rapids📍 St Louis📍 Pittsburgh AstraZeneca · Tests: AZD6750, rilvegostomig A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs NCT06228326Phase 1, Phase 214 sites📍 Dothan📍 Scottsdale📍 Beverly Hills Krystal Biotech, Inc. · Tests: KB707, Pembrolizumab (KEYTRUDA®), Chemotherapy, Docetaxel A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors NCT06747585Phase 1, Phase 241 sites📍 Scottsdale📍 Fullerton📍 Los Angeles Alentis Therapeutics AG · Tests: ALE.P02, Pembrolizumab Analysis of Circulating Tumor DNA Dynamics to Predict and Monitor Response to TKI in Patients With Advanced NSCLC. NCT06167460n/a1 site📍 Ho Chi Minh City Gene Solutions A Study of NX-1607 in Adults With Advanced Malignancies NCT05107674Phase 117 sites📍 Duarte📍 Los Angeles📍 San Francisco Nurix Therapeutics, Inc. · Tests: NX-1607, Paclitaxel A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation NCT07231068Phase 1, Phase 25 sites📍 Beijing📍 Beijing📍 Guangzhou Henan Genuine Biotech Co., Ltd. · Tests: Dositinib mesylate tablets A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases NCT07143045n/a34 sites📍 Hefei📍 Beijing📍 Beijing Alpha Biopharma (Jiangsu) Co., Ltd. · Tests: zorifertinib Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer NCT07250477Phase 24 sites📍 Chico📍 Marysville📍 Sacramento University of California, Davis · Tests: Systemic (ICI)-based therapy informed by the PROphet CB assay and the CARG-TT assessment., Standard of Care A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer NCT06512051Phase 1, Phase 21 site📍 Beijing Shanghai Hengrui Pharmaceutical Co., Ltd. · Tests: SHR-A2102 for Injection, Adebrelimab Injection, Cisplatin injection, Carboplatin injection, Bevacizumab Injection Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib NCT04486833Phase 1, Phase 210 sites📍 Los Angeles📍 Lone Tree📍 Urbana Genprex, Inc. · Tests: quaratusugene ozeplasmid, osimertinib, Platinum-Based Chemotherapy
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy